arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Immunocore Holdings plc

IMCR
$34.01 ▼ -0.52 (-1.51%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
16 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Immunocore Holdings plc faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.7B
Dividend Yield
Revenue Growth 13.6%
Op. Margin 6.8%
ROIC 1.8%
FCF / Share $-0.31
Trailing P/E 130.8x
Price / Book 4.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$106.68M
↑ +13.6%
Net Income Profit after all expenses
$12.97M
↑ +158.2%
Operating Margin Operating profit as % of sales
6.8%
↑ +136.2% 14th
FCF / Share Free cash flow per share
$-0.31
↓ -196.9%
Long-Term Debt Long-term obligations
$438.69M
↓ -3.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
16
Returns
35
Financial Health
38
Cash Quality
37

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 16 quarters